These results strengthen the already known benefits of SGLT2 inhibitors in reducing the risk for HF hospitalization and cardiovascular death in patients with HFrEF as well as in high-risk groups, those with type 2 diabetes or chronic kidney disease. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.